Carbapenem-based Antibiotics Market
Carbapenem-based Antibiotics Market Size, Trend Analysis & Competition Tracking By Product Type (Meropenem, Ertapenem, Panipenem, Tebipenem), By Indication (Intra-abdominal Infections, Bacterial Meningitis, Skin and Skin Structure Infections, Acute Pelvic Infections) - Global Market Insights 2021 to 2031
Analysis of Carbapenem-based Antibiotics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Carbapenem-based Antibiotics Market to Register Strong Growth, on Back of Increasing Incidence of Hospital Acquired Pneumonia and Bacterial Infections
Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.
As per the Center for Disease Control (CDC), people admitted to hospital settings due to various reasons such as immunosuppressive treatment and inappropriately followed infection control protocol, suffer from hospital-acquired pneumonia (HAP). Along with HAP, incidence of various bacterial diseases is increasing rapidly, which in turn is expected to drive the growth of the carbapenem-based antibiotics market.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Surgery-Associated Bacterial Infection to Boost Demand for Carbapenem-Based Antibiotics
Some forms of chronic diseases often require open surgery as a treatment protocol. Before performing open surgery, carbapenem-based antibiotics are often administered as the prophylactic measure for the prevention of surgery-related bacterial infections.
The World Health Organization also emphasizes on infection control protocol i.e. prophylactic administration of the carbapenem-based antibiotics that can limit or eliminate the chances of surgery-associated bacterial infection. As per WHO, 30% of global disease burden is accruing to surgery related diseases pointing towards a heightened demand for prophylactic, carbapenem-based antibiotics.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Carbapenem-based Antibiotics Market Gains Traction, with Generic Alternatives to Ertapenem to be Lucrative Revenue Pockets
Ertapenem is one of the most widely used carbapenem-based antibiotics and its patent expired in November 2017. Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions.
For instance, in June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection. Invanz is Merck Sharp and Dohme Corp.’s joint carbapenem-based antibiotic product for the treatment of various bacterial infections. The launch of various generic version of carbapenem-based antibiotics such as ertapenem in regions such as North America and Europe is expected to offer substantial revenue generation opportunities.
Lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to enhance geographical footprint in lower- and middle-income countries. Increasing supply-chain operations in regions such as North America, East Asia and Europe will further give impetus to high revenue generating carbapenem-based antibiotics markets.
Competitive Landscape
- Pfizer Inc.
- Merck Co. & Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018.
Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Carbapenem-based Antibiotics Market
Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments - product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.
| Product Type |
|
| Indication |
|
| Sales Channel |
|
| Region |
|
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 3.3. Technology Roadmap 4. Key Success Factors 4.1. New Product Launches and Approvals 4.2. Consumption of Carbapenem-based Antibiotics 4.3. Promotional and Marketing Strategies 5. Global Carbapenem-based Antibiotics Market Demand (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029 5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018 5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.2. Forecast Factors - Relevance & Impact 6.3. Regulatory Scenario 6.4. Market Dynamics 6.4.1. Drivers 6.4.2. Restraints 6.4.3. Opportunity Analysis 7. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Product Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2014 - 2018 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2019 - 2029 7.3.1. Meropenem 7.3.2. Ertapenem 7.3.3. Imipenem 7.3.4. Doripenem 7.3.5. Panipenem 7.3.6. Tebipenem 7.4. Market Attractiveness Analysis By Product Type 8. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029 8.3.1. Intra-abdominal Infections 8.3.2. Urinary Tract Infections 8.3.3. Pneumonia 8.3.4. Bacterial Meningitis 8.3.5. Skin and Skin Structure Infections 8.3.6. Acute Pelvic Infections 8.3.7. Prophylaxis of Surgical Site Infection 8.3.8. Respiratory Tract Infections 8.3.9. Gynaecologic Infections 8.3.10. Endocarditis 8.3.11. Others 8.4. Market Attractiveness Analysis By Indication 9. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Sales Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Sales Channel, 2014 - 2018 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Sales Channel, 2019 - 2029 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies & Drug Stores 9.3.3. Online Pharmacies 9.4. Market Attractiveness Analysis By Sales Channel 10. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Region 10.1. Introduction 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2014 - 2018 10.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2019 - 2029 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia 10.3.6. Oceania 10.3.7. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 11.1. Introduction 11.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 11.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 11.3.1. By Country 11.3.1.1. U.S. 11.3.1.2. Canada 11.3.2. By Product Type 11.3.3. By Indication 11.3.4. By Sales Channel 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Product Type 11.4.3. By Indication 11.4.4. By Sales Channel 11.5. Drivers and Restraints - Impact Analysis 12. Latin America Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 12.1. Introduction 12.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 12.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Rest of Latin America 12.3.2. By Product Type 12.3.3. By Indication 12.3.4. By Sales Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product Type 12.4.3. By Indication 12.4.4. By Sales Channel 12.5. Drivers and Restraints - Impact Analysis 13. Europe Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 13.1. Introduction 13.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 13.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. U.K. 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Rest of Europe 13.3.2. By Product Type 13.3.3. By Indication 13.3.4. By Sales Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product Type 13.4.3. By Indication 13.4.4. By Sales Channel 13.5. Drivers and Restraints - Impact Analysis 14. South Asia Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 14.1. Introduction 14.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 14.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Thailand 14.3.1.3. Indonesia 14.3.1.4. Malaysia 14.3.1.5. Rest of South Asia 14.3.2. By Product Type 14.3.3. By Indication 14.3.4. By Sales Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product Type 14.4.3. By Indication 14.4.4. By Sales Channel 14.5. Drivers and Restraints - Impact Analysis 15. East Asia Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 15.1. Introduction 15.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 15.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Product Type 15.3.3. By Indication 15.3.4. By Sales Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product Type 15.4.3. By Indication 15.4.4. By Sales Channel 15.5. Drivers and Restraints - Impact Analysis 16. Oceania Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 16.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Product Type 16.3.3. By Indication 16.3.4. By Sales Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product Type 16.4.3. By Indication 16.4.4. By Sales Channel 16.5. Drivers and Restraints - Impact Analysis 17. Middle East and Africa Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029 17.1. Introduction 17.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018 17.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Turkey 17.3.1.3. Northern Africa 17.3.1.4. South Africa 17.3.1.5. Rest of Middle East and Africa 17.3.2. By Product Type 17.3.3. By Indication 17.3.4. By Sales Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product Type 17.4.3. By Indication 17.4.4. By Sales Channel 17.5. Drivers and Restraints - Impact Analysis 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Share Analysis of Top Players, by Region 18.3. Market Presence Analysis 18.3.1. By Regional footprint of Players 18.3.2. Product foot print by Players 18.3.3. Channel Foot Print by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive (Tentative List) 19.3.1. ACS Dobfar S.p.A. 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Profitability by Market Segments (Product/Channel/Region) 19.3.1.4. Sales Footprint 19.3.1.5. Strategy Overview 19.3.1.5.1. Marketing Strategy 19.3.1.5.2. Product Strategy 19.3.1.5.3. Channel Strategy 19.3.2. Amneal Pharmaceuticals LLC 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Profitability by Market Segments (Product/Channel/Region) 19.3.2.4. Sales Footprint 19.3.2.5. Strategy Overview 19.3.2.5.1. Marketing Strategy 19.3.2.5.2. Product Strategy 19.3.2.5.3. Channel Strategy 19.3.3. Apotex, Inc. 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Profitability by Market Segments (Product/Channel/Region) 19.3.3.4. Sales Footprint 19.3.3.5. Strategy Overview 19.3.3.5.1. Marketing Strategy 19.3.3.5.2. Product Strategy 19.3.3.5.3. Channel Strategy 19.3.4. Aurobindo Pharma Ltd. 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Profitability by Market Segments (Product/Channel/Region) 19.3.4.4. Sales Footprint 19.3.4.5. Strategy Overview 19.3.4.5.1. Marketing Strategy 19.3.4.5.2. Product Strategy 19.3.4.5.3. Channel Strategy 19.3.5. Daewoong Pharmaceutical Co., Ltd. 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Profitability by Market Segments (Product/Channel/Region) 19.3.5.4. Sales Footprint 19.3.5.5. Strategy Overview 19.3.5.5.1. Marketing Strategy 19.3.5.5.2. Product Strategy 19.3.5.5.3. Channel Strategy 19.3.6. Fedora Pharmaceuticals, Inc. 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Profitability by Market Segments (Product/Channel/Region) 19.3.6.4. Sales Footprint 19.3.6.5. Strategy Overview 19.3.6.5.1. Marketing Strategy 19.3.6.5.2. Product Strategy 19.3.6.5.3. Channel Strategy 19.3.7. Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.) 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Profitability by Market Segments (Product/Channel/Region) 19.3.7.4. Sales Footprint 19.3.7.5. Strategy Overview 19.3.7.5.1. Marketing Strategy 19.3.7.5.2. Product Strategy 19.3.7.5.3. Channel Strategy 19.3.8. Iterum Therapeutics plc 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Profitability by Market Segments (Product/Channel/Region) 19.3.8.4. Sales Footprint 19.3.8.5. Strategy Overview 19.3.8.5.1. Marketing Strategy 19.3.8.5.2. Product Strategy 19.3.8.5.3. Channel Strategy 19.3.9. Jeil Pharmaceutical Co., Ltd. 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Profitability by Market Segments (Product/Channel/Region) 19.3.9.4. Sales Footprint 19.3.9.5. Strategy Overview 19.3.9.5.1. Marketing Strategy 19.3.9.5.2. Product Strategy 19.3.9.5.3. Channel Strategy 19.3.10. Johnson & Johnson Pharmaceuticals 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Profitability by Market Segments (Product/Channel/Region) 19.3.10.4. Sales Footprint 19.3.10.5. Strategy Overview 19.3.10.5.1. Marketing Strategy 19.3.10.5.2. Product Strategy 19.3.10.5.3. Channel Strategy 19.3.11. Meiji Seika Pharma Co., Ltd. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Profitability by Market Segments (Product/Channel/Region) 19.3.11.4. Sales Footprint 19.3.11.5. Strategy Overview 19.3.11.5.1. Marketing Strategy 19.3.11.5.2. Product Strategy 19.3.11.5.3. Channel Strategy 19.3.12. Merck & Co., Inc. 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Profitability by Market Segments (Product/Channel/Region) 19.3.12.4. Sales Footprint 19.3.12.5. Strategy Overview 19.3.12.5.1. Marketing Strategy 19.3.12.5.2. Product Strategy 19.3.12.5.3. Channel Strategy 19.3.13. Pfizer, Inc. 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Profitability by Market Segments (Product/Channel/Region) 19.3.13.4. Sales Footprint 19.3.13.5. Strategy Overview 19.3.13.5.1. Marketing Strategy 19.3.13.5.2. Product Strategy 19.3.13.5.3. Channel Strategy 19.3.14. Savior Lifetec Corporation 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Profitability by Market Segments (Product/Channel/Region) 19.3.14.4. Sales Footprint 19.3.14.5. Strategy Overview 19.3.14.5.1. Marketing Strategy 19.3.14.5.2. Product Strategy 19.3.14.5.3. Channel Strategy 19.3.15. Spero Therapeutics, Inc. 19.3.15.1. Overview 19.3.15.2. Product Portfolio 19.3.15.3. Profitability by Market Segments (Product/Channel/Region) 19.3.15.4. Sales Footprint 19.3.15.5. Strategy Overview 19.3.15.5.1. Marketing Strategy 19.3.15.5.2. Product Strategy 19.3.15.5.3. Channel Strategy 19.3.16. Sumitomo Dainippon Pharma Co., Ltd. 19.3.16.1. Overview 19.3.16.2. Product Portfolio 19.3.16.3. Profitability by Market Segments (Product/Channel/Region) 19.3.16.4. Sales Footprint 19.3.16.5. Strategy Overview 19.3.16.5.1. Marketing Strategy 19.3.16.5.2. Product Strategy 19.3.16.5.3. Channel Strategy 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Region
Table 02: Global Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Product Type
Table 03: Global Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Indication
Table 04: Global Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Sales Channel
Table 05: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 06: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 07: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 08: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 09: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 10: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 11: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 12: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 13: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 14: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 15: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 16: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 17: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 18: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 19: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 20: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 21: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 22: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 23: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 24: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 25: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 26: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 27: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 28: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 29: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 30: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 31: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 32: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 33: Emerging countries Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014-2018 and Forecast 2019–2029, By region
Table 34: China Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 35: China Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 36: China Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 37: India Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 38: India Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 39: India Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
Table 40: Brazil Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Product Type
Table 41: Brazil Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Indication
Table 42: Brazil Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Sales Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Carbapenem-based Antibiotics Market Value Analysis and Forecast, 2017–2029 (US$ Mn)
Figure 02: Global Carbapenem-based Antibiotics Market Value Opportunity Assessment, 2019-2029
Figure 03: Global Carbapenem-based Antibiotics Revenue Share by Region, 2019E and 2029F
Figure 04: Global Carbapenem-based Antibiotics Market Attractiveness Analysis, By Region, 2019E
Figure 05: Global Carbapenem-based Antibiotics Revenue Share (in US$ Mn) by Product Type, 2019E and 2029F
Figure 06: Global Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type, 2019E
Figure 07: Global Carbapenem-based Antibiotics Revenue Share by Indication, 2019E and 2029F
Figure 08: Global Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication, 2019E
Figure 09: Global Carbapenem-based Antibiotics Revenue Share by Sales Channel, 2019E and 2029F
Figure 10: Global Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel, 2019E
Figure 11: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 12: North America Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 13: North America Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 14: North America Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 15: North America Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 16: North America Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 17: North America Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 18: North America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 19: North America Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 20: North America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 21: North America Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 22: North America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 23: North America Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 24: North America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 25: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 26: Latin America Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 27: Latin America Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 28: Latin America Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 29: Latin America Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 30: Latin America Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 31: Latin America Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 32: Latin America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 33: Latin America Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 34: Latin America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 35: Latin America Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 36: Latin America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 37: Latin America Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 38: Latin America Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 39: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 40: Europe Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 41: Europe Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 42: Europe Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 43: Europe Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 44: Europe Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 45: Europe Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 46: Europe Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 47: Europe Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 48: Europe Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 49: Europe Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 50: Europe Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 51: Europe Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 52: Europe Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 53: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 54: South Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 55: South Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 56: South Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 57: South Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 58: South Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 59: South Asia Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 60: South Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 61: South Asia Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 62: South Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 63: South Asia Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 64: South Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 65: South Asia Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 66: South Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 67: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 68: East Asia Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 69: East Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 70: East Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 71: East Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 72: East Asia Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 73: East Asia Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 74: East Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 75: East Asia Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 76: East Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 77: East Asia Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 78: East Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 79: East Asia Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 80: East Asia Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 81: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 82: Oceania Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 83: Oceania Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 84: Oceania Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 85: Oceania Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 86: Oceania Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 87: Oceania Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 88: Oceania Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 89: Oceania Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 90: Oceania Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 91: Oceania Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 92: Oceania Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 93: Oceania Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 94: Oceania Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 95: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 96: MEA Carbapenem-based Antibiotics Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 97: MEA Carbapenem-based Antibiotics Market Value Share 2019E, By Product Type
Figure 98: MEA Carbapenem-based Antibiotics Market Value Share 2019E, By Indication
Figure 99: MEA Carbapenem-based Antibiotics Market Value Share 2019E, By Sales Channel
Figure 100: MEA Carbapenem-based Antibiotics Market Value Share 2019E, By Country
Figure 101: MEA Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Country
Figure 102: MEA Carbapenem-based Antibiotics Market Attractiveness Analysis, By Country
Figure 103: MEA Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Product Type
Figure 104: MEA Carbapenem-based Antibiotics Market Attractiveness Analysis, By Product Type
Figure 105: MEA Carbapenem-based Antibiotics Market Value Share Analysis 2019E & 2029F, By Indication
Figure 106: MEA Carbapenem-based Antibiotics Market Attractiveness Analysis, By Indication
Figure 107: MEA Carbapenem-based Antibiotics Market Value Share Analysis, 2019E & 2029F, By Sales Channel
Figure 108: MEA Carbapenem-based Antibiotics Market Attractiveness Analysis, By Sales Channel
Figure 109: Emerging countries Carbapenem-based Antibiotics Market Size (US$ Mn) Analysis, 2014–2018
Figure 110: Emerging countries Carbapenem-based Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2019 – 2029
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which company received FDA approval for generic Invanz injection in Carbapenem?
In June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection.
What are the product type of Carbapenem-based Antibiotics Market?
Meropenem,Ertapenem,Doripenem,Panipenem,Tebipenem are the product types of Carbapenem-based Antibiotics Market.
Carbapenem-based Antibiotics Market